Abstract:Background: Polymyxins have been revived as a last-line therapeutic option for multi-drug resistant bacteria and continue to account for a significant proportion of global antibiotic usage. However, kidney injury is often a treatment limiting event with kidney failure rates ranging from 5 to 13%. The mechanisms underlying polymyxin-induced nephrotoxicity are currently unclear. Researches of polymyxin-associated acute kidney injury (AKI) models need to be more standardized, which is crucial for obtaining consistent and robust mechanistic results. Methods: In this study, male C57BL/6 mice received different doses of polymyxin B (PB) and polymyxin E (PE, also known as colistin) by different routes once daily (QD), twice daily (BID), and thrice daily (TID) for 3 days. We continuously monitored the glomerular filtration rate (GFR) and the AKI biomarkers, including serum creatinine (Scr), blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1). We also performed histopathological examinations to assess the extent of kidney injury. Results: Mice receiving PB (35 mg/kg/day subcutaneously) once daily exhibited a significant decrease in GFR and a notable increase in KIM-1 two hours after the first dose. Changes in GFR and KIM-1 at 24, 48 and 72 h were consistent and demonstrated the occurrence of kidney injury. Histopathological assessments showed a positive correlation between the severity of kidney injury and the changes in GFR and KIM-1 (Spearman's rho = 0.3167, P = 0.0264). The other groups of mice injected with PB and PE did not show significant changes in GFR and AKI biomarkers compared to the control group. Conclusion: The group receiving PB (35 mg/kg/day subcutaneously) once daily consistently developed AKI at 2 h after the first dose. Establishing an early and stable AKI model facilitates researches into the mechanisms of early-stage kidney injury. In addition, our results indicated that PE had less toxicity than PB and mice receiving the same dose of PB in the QD group exhibited more severe kidney injury than the BID and TID groups.

Determinants of Preferential Renal Accumulation of Synthetic Polymers in Acute Kidney Injury.

Recent Advances in Engineered Nanomaterials for Acute Kidney Injury Theranostics

Natural products applied in acute kidney injury treatment: polymer matters

Megalin-targeted acetylcysteine polymeric prodrug ameliorates ischemia-reperfusion-induced acute kidney injury

Natural ursolic acid based self-therapeutic polymer as nanocarrier to deliver natural resveratrol for natural therapy of acute kidney injury

1,2-Bis(2-aminophenoxy)ethane- N, N, N', N'-tetraacetic Acid Acetoxymethyl Ester Loaded Reactive Oxygen Species Responsive Hyaluronic Acid-Bilirubin Nanoparticles for Acute Kidney Injury Therapy via Alleviating Calcium Overload Mediated Endoplasmic Reticulum Stress

Size and Temporal-Dependent Efficacy of Oltipraz-Loaded PLGA Nanoparticles for Treatment of Acute Kidney Injury and Fibrosis

Poly (ADP-Ribose) Polymerase Inhibitor Treatment as a Novel Therapy Attenuating Renal Ischemia-Reperfusion Injury

Intravenous Calcium Alginate Microspheres as Drug Delivery Vehicles in Acute Kidney Injury Treatment

Nanoparticles constructed from natural polyphenols are used in acute kidney injury

Enhanced Efficiency of Mitochondria-Targeted Peptide SS-31 for Acute Kidney Injury by Ph-Responsive and AKI-kidney Targeted Nanopolyplexes.

Self-Assembled Phytochemical Nanomedicines with Enhanced Bioactivities for Effective Acute Kidney Injury Therapy

Self-polymerized polydopamine-based nanoparticles for acute kidney injury treatment through inhibiting oxidative damages and inflammatory

An early and stable mouse model of polymyxin-induced acute kidney injury

Sequential Therapy of Acute Kidney Injury with a DNA Nanodevice

Engineered Nanodrug Targeting Oxidative Stress for Treatment of Acute Kidney Injury

Design, synthesis and biological evaluation of novel arylpropionic esters for the treatment of acute kidney injury

Multi-enzyme mimetic ultrasmall iridium nanozymes as reactive oxygen/ nitrogen species scavengers for acute kidney injury management

Ultrasmall Platinum Nanozymes As Broad-Spectrum Antioxidants for Theranostic Application in Acute Kidney Injury

A Polymeric Nanosponge as a Broad-Spectrum Reactive Oxygen Species Scavenger for Acute Kidney Injury Treatment

Phenylenediamine-Based Carbon Nanodots Alleviate Acute Kidney Injury Via Preferential Renal Accumulation and Antioxidant Capacity.